RESULTS	At week 12 , significant reductions in HbA1c were observed in all canagliflozin groups relative to placebo ( -0.61 , -0.80 , -0.79 and -0.88 % for 50 , 100 , 200 and 300mg , respectively , versus +0.11 % for placebo ; all , p < 0.01 ) .\